In partnership with BostonWorks
Sunday, May 6, 2007
Seaport World Trade Center
11am - 6pm
FREE Educational Sessions
Beacon Hill Complex -- Seaport World Trade Center
Please join Ms. Pearl Freier of Cambridge BioPartners as she presents the following educational sessions at the 2007 BIO Career Fair, Sunday, May 6th. These are free sessions but seating is limited.
1st Workshop session: Sunday, May 6th
11:30 am -- 12:30 am
Marketing Yourself to Your Future Employer in Biotech and Pharma
Job Seekers, bring your questions and your concerns to this terrific session. Get some new ideas for networking in the scientific community and tips for putting together your personal marketing plan and toolkit.
2nd Panel session: Sunday, May 6th
2:00 pm -- 3:00 pm
Moving Your Career Forward in the Biotech and Pharmaceutical Industries
This panel discussion will include scientific leaders and human resources executives from companies including AstraZeneca, Merck, Synta Pharmaceuticals, and Vertex Pharmaceuticals to discuss growth opportunities in the industry, employers' perspectives on what makes an attractive candidate, and suggestions for transitioning from academia to industry.
VP Human Resources
Arthur J. McMahon
VP Human Resources
Victoria Richon, PhD
Senior Director, Cancer Research
Merck Research Laboratories Boston
Director and HR Business Partner
AstraZeneca R&D Boston
Pearl Freier is President of Cambridge BioPartners, an executive search and workforce strategy firm serving the biopharmaceutical and medical technology industries. Pearl's recruiting methodologies have made her a national authority on recruiting and career strategies in the life sciences. She has appeared in publications including Science, Nature, Bio-ITWorld, The Wall Street Journal, The Boston Globe, and the Boston Business Journal and has delivered presentations for universities and scientific associations throughout North America. Ms. Freier sits on advisory boards at the Massachusetts Technology Leadership Council and the MIT Enterprise Forum of Cambridge, and is a member of BIO's Education and Outreach Committee
Lisa Kelly is currently the Vice President of Human Resources at Vertex Pharmaceuticals. Ms. Kelly has 17 years of experience in a wide range of global and domestic Human Resources leadership roles. Ms. Kelly was most recently the VP of Human Resources at Nitromed, Inc., a biopharmaceutical firm in Lexington, MA, after holding the position of SVP of Healthcare and Service Operations at CIGNA. The majority of her career was spent in a variety of assignments at Frito Lay, Inc. and The Monsanto Company including an international assignment based in Singapore. Ms. Kelly attended the University of Illinois at Urbana-Champaign where she received a B.S. in Finance and an M.A. in Labor and Industrial Relations. Ms. Kelly is a past recipient of the Hartford Business Journal's "Top 40 Under 40" Award.
Arthur J. McMahon joined Synta Pharmaceuticals as Vice President, Human Resources in January 2007. From 2001 until joining Synta, Mr. McMahon served as Senior Director of Human Resources for Cabot Corporation, a publicly traded specialty chemical company. From 1995 to 2001, Mr. McMahon was Vice President of Human Resources for Osprey Systems, Inc., a privately owned software and information technology services company. Mr. McMahon's past experience in the field of human resources also includes positions with Broadway and Seymour, Inc., Wang Laboratories, Inc. and Raytheon Company. Mr. McMahon earned his B.S. from North Carolina State University and his J.D. from Suffolk University Law School.
Victoria Richon joined Merck Research Laboratories Boston as Senior Director of Cancer Biology and Therapeutics following Merck's 2004 acquisition of Aton Pharma, Inc. Dr. Richon was a co-founder at Aton and served as Executive Director of Biology. She currently heads MRL Boston's Department of Cancer Biology and Therapeutics. Dr. Richon was a leading member of the scientific group that discovered the histone deacetylase inhibitor vorinostat (SAHA or suberoylanilide hydroxamic acid). Marketed under the name ZolinzaTM, it was approved by the U.S. Food and Drug Administration in October 2006 for the treatment of cutaneous manifestations in patients with cutaneous T-cell lymphoma (CTCL), a form of non-Hodgkin's lymphoma, who have progressive, persistent or recurrent disease on or following two systemic therapies. Zolinza is the first histone deacetylase inhibitor approved for the treatment of cancer. Dr. Richon received her B.A. in Chemistry from the University of Vermont in 1981 and her Ph.D. in Biochemistry at the University of Nebraska in 1986. She completed her post-doctoral research in the laboratory of Drs. Paul Marks and Richard Rifkind at Memorial Sloan-Kettering Cancer Center from 1986 until 1989.
Rachel R. Strauss is Director of Human Resources at AstraZeneca, a global pharmaceutical company. She currently works as the HR lead at AstraZeneca R&D Boston. Before joining AstraZeneca in 2001, Rachel worked at Bristol Myers Squibb providing Human Resources support to Sales, R&D and the International Medicines Division in Paris, France. She has a diverse industry background with experience at MIT, General Electric and Staples. She graduated from the University of Massachusetts at Amherst and has a Masters of Human Resources from the University of Illinois at Urbana-Champaign.